

Linked report — data-training provisions in filed drug-discovery alliances dated 2020 or later

Every line below except the headings and this note is copied verbatim from the generated analysis report

Product_Roadmap/Ex10_provisions/topics/data_training/analyze/report.md (observation tags removed), or rendered from the review findings ledgers analyze/R3b/ledger.json and analyze/R3c/ledger.json. Nothing here is retyped.

Population

The candidate set is 152 folders (topic listed, D1 year 2020 or later, or no printed date). 38 are coded alliance rows and 114 are excluded. Every exclusion is listed below with its basis; 1 rest on the MANIFEST date rule and have no quotable text.

dispositions

disposition	folders
NOT_IDENTIFIABLE_AS_AI	57
IN_COHORT	38
NOT_AI	22
NOT_ALLIANCE	17
NOT_DRUG_DISCOVERY	11
DATA_OR_SERVICES_ONLY	5
COMMENCED_PRE2020	1
COMMENCED_UNKNOWN_PRE2020	1

The split between NOT_AI (22) and NOT_IDENTIFIABLE_AS_AI (57) is reader judgment (codebook ADJ-1); only the combined count, 79, is relied on.

excluded folder	disposition	basis (deciding span first)	obs
ADARx-PuertoRico Collaboration-and- License-Option 2025-05-09	NOT_AI	[[1.34. "ADARx Platform" means ADARx's proprietary mRNA Silencing Technology (MSTTM) and Cell Targeted Delivery (CTDTM) technology,	

excluded folder	disposition	basis (deciding span first)	obs
Acrivon-Akoya Oncosignature- Companion- Diagnostic 2022-06-17	NOT_DRUG_DISCOVERY	including proprietary (a) chem ...]] [[WHEREAS, Acrivon and Akoya desire to further collaborate for Akoya to develop, validate, obtain regulatory approval for, and commercialize a companion diagnosti ...]]	
Adaptimmune- Galapagos Collaboration-and- Exclusive-License 2024-05-30	NOT_AI	[[1.13 “Adaptimmune Manufacturing Platform” means Adaptimmune’s cell therapy autologous manufacturing platform used to manufacture the Adaptimmune Product for use ...]]	
Adaptimmune- Genentech Strategic- Collaboration-and- License 2021-09-03	NOT_IDENTIFIABLE_AS_AI	[[12.1.5. “GNE Proprietary Platform Methods” means GNE’s proprietary processes or technology for making, engineering or developing Cell Therapies,	

excluded folder	disposition	basis (deciding span first)	obs
		including [***]. ...]]	
Adimab-Adagio Assignment-and- License 2020-07-08	NOT_IDENTIFIABLE_AS_AI	[[1.17 “Adimab Platform Technology” means (a) methods of discovery and optimization of antibodies, which methods include [***], (b) all methods, materials and oth ...]]	
Aktis-EliLilly License-Research- and-Collaboration 2024-05-16	NOT_IDENTIFIABLE_AS_AI	[[1.12 “Aktis Platform” means Aktis’ or any of its Affiliates’ proprietary platform to discover and develop therapeutics or diagnostics for cancer using radioliga ...]]	
Alcon-RxSight License- Collaboration-and- Development 2026- 06-30	NOT_DRUG_DISCOVERY	[[WHEREAS, RxSight is a medical technology company engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses; WHEREAS, ...]]	

excluded folder	disposition	basis (deciding span first)	obs
Alector-GlaxoWellcome Collaboration-and-License 2021-07-01	NOT_IDENTIFIABLE_AS_AI	[[1.6 “Alector Intellectual Property” means Alector Know-How, Alector Patents, Alector’s interest in the Joint Patents, Alector Sole Inventions, and Alector Platf ...]]	
Allogene-AllogeneOverland Exclusive-License 2020-12-14	NOT_IDENTIFIABLE_AS_AI (ADJ-1)	[[1.14 “Allogene Platform” shall mean [***].]]	
Alloy-Prometheus License 2020-03-18	NOT_IDENTIFIABLE_AS_AI	[[“ATX Know-How” means the Know-How listed on Exhibit A, attached hereto. (f) “ATX Mouse” means a genetically modified humanized mouse provided by ATX to LICENSEE ...]]	
Alnylam-Tenaya Collaboration 2026-03-04	NOT_IDENTIFIABLE_AS_AI	[[“Tenaya Platform Know-How” means, at any given time during the Term, [***]. Tenaya Platform Know-How includes Tenaya Platform Improvements, but shall not includ ...]]	

excluded folder	disposition	basis (deciding span first)	obs
Amgen-GenerateBiomedicines Collaboration 2021-12-24	NOT_IDENTIFIABLE_AS_AI	[[1.69. "Generate Platform" means [***]. 1.70. "Generate Platform Activities" means [***].]]	
Amunix-Vir License 2024-07-31	NOT_AI	[[1.H "Amunix Platform" means all accessory-modified polypeptides that (a) include at least one accessory polypeptide, and (b) include at least one biologically ac ...]]	
Arbutus-KarenSims Consulting 2025-03-28	NOT_ALLIANCE:consulting	[[CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Agreement ...]]	
AsprBarda-Gritstonebio Award-Contract 2023-09-27	NOT_ALLIANCE:services_government_award_contract	[[Independently and not as an agent of the Government, the Contractor shall furnish all the necessary	

excluded folder	disposition	basis (deciding span first)	obs
		services, qualified personnel, material, equipment, and faci ...]]	
AstrazenecaAb-Tempus Master-Services 2021-11-17	DATA_OR_SERVICES_ONLY	[[WHEREAS, AstraZeneca and Tempus are, as at the Effective Date, parties to certain agreements including a master services agreement dated 16 December 2018 (“Exis ...]]	
Atreca-Xencor Collaboration-and-License 2020-07-02	NOT_IDENTIFIABLE_AS_AI	[[1.15 “Atreca Platform Technology” means Atreca’s proprietary technologies, processes and methods of [*], and [*], including Atreca’s [*].]]	
Avenzo-DualityBio Collaboration-and-License 2024-12-23	NOT_IDENTIFIABLE_AS_AI	[[1.120 “Licensed Platform Patents” means [***].]]	
Avidity-Bryce License 2025-10-25	NOT_AI	[[1.136 “SpinCo Platform” means the Company’s (as of each of the Original	

excluded folder	disposition	basis (deciding span first)	obs
		Execution Date and the Execution Date) or SpinCo's (as of the Effective Date) platform t ...]]	
BioXcel-DrKrishnan-InveniAI-Invea Non-Compete 2023-09-19	NOT_ALLIANCE:non_compete_and_ip_release_settlement	[[THIS NON-COMPETE AGREEMENT (the "Agreement") is made and entered into as of September 19, 2023 (the "Effective Date"), by and among BioXcel Therapeutics, Inc. (...]]	
Biohaven-Sk License 2026-08-26	NOT_IDENTIFIABLE_AS_AI	[[1.88"Kv7 Discovery Platform" means the technology platform for the discovery and optimization of compounds that modulate the Kv7 protein [***], as such platform ...]]	
Biotheus-BioNTech Collaboration-License-and-Option 2023-10-26	NOT_IDENTIFIABLE_AS_AI	[[means the Patent Rights and Know-How relating to Biotheus' proprietary platform technology and set out or	

excluded folder	disposition	basis (deciding span first)	obs
BoehringerIngelheim-Cue Collaboration-and-License 2025-04-10	NOT_AI	described in Schedule 6. Such Schedule may be updated ...]] [[WHEREAS, CUE is biopharma company focused on biologic therapies for oncology and immunology driven diseases; WHEREAS, BI recognizes CUE's expertise in the field ...]]	
BoehringerIngelheim-Palatin Research-Collaboration-License-and-Patent-Assignment 2025-08-14	NOT_AI	[[WHEREAS, PALATIN is specialized in the discovery and development of novel melanocortin receptor agonists for the treatment of patients living with retinopathies ...]]	
BristolMyers-Avidity Research-Collaboration-and-License 2023-11-27	NOT_IDENTIFIABLE_AS_AI	[[1.7 "Avidity AOC Platform Technology" means (a) the proprietary Know-How within the Avidity Know-How as of the Effective Date	

excluded folder	disposition	basis (deciding span first)	obs
Candid-Wuxi License 2025-01-02	NOT_AI	consisting of [***]. The Avidity AO ...]] [[Platform Technology” means WuXi Biologics’ proprietary technology to generate a bispecific, tri-specific or other multi-specific antibody that may be used to ge ...]]	
Caribou-AbbVie Collaboration-and-License 2021-02-09	NOT_IDENTIFIABLE_AS_AI	[[“Caribou Platform Technology” means all Caribou Cas12a chRDNA Technology and all Caribou CAR-T Technology owned or Controlled by Caribou or any of its Affiliate ...]]	
Codiak-LonzaRockland License-and-Collaboration 2021-11-15	NOT_IDENTIFIABLE_AS_AI (ADJ-1)	[[“Codiak Platform Manufacturing Technology” means [***].]]	
Codiak-Sarepta Research-License-and-Option 2020-06-17	NOT_IDENTIFIABLE_AS_AI	[[“Codiak Proprietary Platform” means [***].]]	
Crescent-CharlesRiver Master-Contract-	NOT_ALLIANCE:services	[[THIS MASTER CONTRACT SERVICES	

excluded folder	disposition	basis (deciding span first)	obs
Services 2024-12-06		AGREEMENT (together with Appendices A and any Statement(s) of Work (as defined in Section 1), the “Agreement”) is made as of the l ...]]	
CytomX-Astellas Collaboration-and-License 2020-03-23	NOT_AI	[[WHEREAS, CytomX has technology and expertise relating to the discovery and development of bi-specific recombinant antibodies directed to certain targets using i ...]]	
CytomX-ModernaTX Collaboration-and-License 2022-12-30	NOT_IDENTIFIABLE_AS_AI	[[“CytomX Platform Improvements IP” means [***]. Section 1.49 “CytomX Platform Know-How” means [***]. Section 1.50 “CytomX Platform Patents” means [***]. Section ...]]	
CytomX-Regeneron Collaboration-and-License 2022-11-16	NOT_IDENTIFIABLE_AS_AI (ADJ-1)	[[“CytomX Platform Technology” means [***].]]	
Dyadic-	NOT_DRUG_DISCOVERY	[[Leprino is [***]	

excluded folder	disposition	basis (deciding span first)	obs
LeprinoFoods Joint-Development 2022-05-12		and a global leader in the production and sale of [***]dairy products. Leprino is interested in collaborating with Dyadic on development of com ...]]	
EliLilly-TrexBio-Trex Research-Collaboration-and-License 2023-01-06	NOT_IDENTIFIABLE_AS_AI	[[1.169. "Trex Platform Technology" means Trex's proprietary target discovery platform referred to as the Deep Biology Platform and described in Schedule 1.169 (T ...]]	
FStar-Janssen License-and-Collaboration 2021-10-19	NOT_AI	[[1.57 "Fcab" means the antigen binding loops in the CH3 domain of the Fc region of an Antibody that confers specific binding of the Fc region to the Fcab Target.]]	
Fate-Janssen Collaboration-and-Option 2020-04-02	NOT_IDENTIFIABLE_AS_AI	[[1.59 "Fate Platform Technology" means Patents and Know-How Controlled by	

excluded folder	disposition	basis (deciding span first)	obs
		Fate or its Affiliates as of the Effective Date or at any time during the Term that comp ...]]	
Foghorn-Eli Lilly Collaboration 2021-12-10	NOT_IDENTIFIABLE_AS_AI	[[1.73“Foghorn Platform” means an integrated gene traffic control platform Controlled by or proprietary to Foghorn as of the Effective Date and during the term of ...]]	
Foghorn-MSD Research-Collaboration-and-Exclusive-License 2020-07-02	NOT_IDENTIFIABLE_AS_AI	[[developed a proprietary integrated gene traffic control platform, which is known as the Gene Traffic Control™ Product Platform (aka GTC™ Product Platform), whic ...]]	
Frameshift Management-Inhibitor Master-Services 2025-10-21	NOT_ALLIANCE:services	[[MASTER SERVICES AGREEMENT (the “Agreement”) is made and entered into as of this 21st day of October, 2025]]	

excluded folder	disposition	basis (deciding span first)	obs
Fusion-AstrazenecaUk Strategic-Collaboration 2020-10-XX	NOT_AI	[[Fusion possesses certain intellectual property, technology and expertise in the field of radioconjugates including conjugates incorporating Fusion's proprietary ...]]	
GSK-Mersana Collaboration-Option-and-License 2022-08-06	NOT_IDENTIFIABLE_AS_AI	[[1.221 "Mersana Platform" means Mersana's proprietary [**] used to conjugate Mersana's proprietary STING Agonist included in the Licensed Compound (also known as ...]]	
GatesVentures-Schrodinger Independent-Contractor 2020-06-23	NOT_ALLIANCE:services_consulting	[[This INDEPENDENT CONTRACTOR AGREEMENT (the "Agreement") is entered into by and between Gates Ventures, LLC ("Company") and Schrödinger, Inc. ("Contracto	

excluded folder	disposition	basis (deciding span first)	obs
Gb-Encore Exclusive-Intellectual-Property-License 2026-06-15	NOT_DRUG_DISCOVERY	r”), as ...]] [[The Licensed Technology includes the exclusive right to use GS Sciences PhAROS AI/software and platforms in all applications of human patient selection, such as ...]]	
Genentech-Pieris Research-Collaboration-and-License 2021-05-19	NOT_AI	[[WHEREAS, Pieris has access to a proprietary Anticalin® (lipocalin derived) discovery and manufacturing platform, possesses proprietary technology and intellectu ...]]	
Gilead-Tango Amended-and-Restated-Research-Collaboration-and-License 2020-08-17	COMMENCED_PRE2020	[[C. The Parties entered into that certain Research Collaboration and License Agreement (the “Original Agreement”), dated October 22, 2018 (the “Original Effectiv ...]]	
GlaxoWellcome-Vir Definitive-	NOT_IDENTIFIABLE_AS_AI	[[5.3.1 With respect to each	

excluded folder	disposition	basis (deciding span first)	obs
Collaboration 2021-03-25		Target or the associated Respiratory Viral Disease that becomes the subject of Screening Data Analysis, each Party will contribute, a ...]]	
Heptares-Neurocrine Collaboration-and-License 2021-11-22	NOT_IDENTIFIABLE_AS_AI	[[Heptares Platform Heptares' proprietary platform covering [***];]]	
Horizon-Arrowhead Collaboration-and-License 2021-06-18	NOT_AI	[[Whereas, Arrowhead possesses proprietary technology and know-how related to the discovery, identification, synthesis and development of RNA interference ("RNAi" ...]]	
Igm-Genzyme Collaboration-and-License 2022-03-28	NOT_IDENTIFIABLE_AS_AI	[[1.162 "IGM Platform" means any [***]. 1.163 "IGM Platform IP" means all IGM Platform Patents and IGM Platform Know-How. 1.164 "IGM Platform Know-How"	

excluded folder	disposition	basis (deciding span first)	obs
Illumina-Customer Illumina-Software- Subscription 2024- 09-03	NOT_ALLIANCE:software_subscription	means any ... [[This Illumina Software Subscription Agreement (together with any Service Addenda (as defined below), the “Agreement”) defines the rights and obligations of Illu ...]]	
ImmaticsBiotechnol ogies-BMS License- Development-and- Commercialization 2021-12-10	NOT_IDENTIFIABLE_AS_AI	[[1.63 “Immatics Platform Know-How” means Know-How owned or Controlled by Immatics or its Affiliates as of the Execution Date or during the Term that [**]; but ex ...]]	
ImmaticsUs- CelgeneSwitzerland Collaboration 2022- 06-01	NOT_IDENTIFIABLE_AS_AI	[[1.81 “Immatics Platform Technology” means (a) the proprietary platform technology owned by Immatics (or any of its Affiliates) that consists of [**] the “Initia ...]]	
ImmunoGen- HangzhouZhongmei	NOT_AI	[[1.95 “ImmunoGen	

excluded folder	disposition	basis (deciding span first)	obs
Collaboration-and-License 2020-10-19		Platform Know-How” means any ImmunoGen Know-How that is [***] to Exploit ImmunoGen’s proprietary antibody-drug conjugate platform technology rel ...]]	
IntegralMolecular-Context Research-Collaboration-and-License 2021-04-06	NOT_IDENTIFIABLE_AS_AI	[[1.37. “Integral Platform” shall have the meaning provided in Exhibit C.]]	
Invea-InveniAI AlphaMeld-License 2023-10-01	NOT_ALLIANCE:software_subscription	[[Invea is a biotechnology company focused on immune mediated inflammatory diseases (IMIDs) and wishes to obtain a license to access and use AlphaMeld® from Inven ...]]	
InveniAI-Invea Shared-Services 2021-11-24	NOT_ALLIANCE:services_agreement	[[This Shared Services Agreement (this “Agreement”) is entered into as of November 24, 2021 (the “Execution Date”), by and between	

excluded folder	disposition	basis (deciding span first)	obs
		InveniAI LLC, a Delaware corpor ...]]	
Janux-BMS Exclusive-License-and-Collaboration 2026-01-21	NOT_IDENTIFIABLE_AS_AI	[[Schedule 1.67 Janux Platform Technology [...***...]]]	
Janux-MSD Research-Collaboration-and-Exclusive-License 2020-12-15	NOT_AI	[[WHEREAS, Company has developed and is the owner of proprietary technology related to conditionally-active T cell engagers that enables the design and engineerin ...]]	
JiangsuHengrui-IDEAYA License 2024-12-27	NOT_IDENTIFIABLE_AS_AI	[[“Hengrui Platform” means technology Controlled by Hengrui to the extent relating to [***].]]	
Kr8Ai-Foxo Letter 2023-10-29	NOT_DRUG_DISCOVERY	[[letter confirms that KR8 AI INC. and FOXO Technologies Inc. have agreed that KR8 will grant and does hereby grant to FOXO a provisional exclusive license (the “ ...]]	
KyleDay-DongThi-TranQuoc-	NOT_ALLIANCE:asset_purchase	[[Sale and Purchase	

excluded folder	disposition	basis (deciding span first)	obs
MuratCetinkaya-GenEmbryomics Sale-and-Purchase 2024-12-15		Agreement of License Rights]]	
KyleDay-GenEmbryomics Development-and-Transfer 2025-01-10	NOT_ALLIANCE:services	[[A. The Seller has agreed to develop and implement: (i) Backlinks from geneticgenie.org to the Buyer's designated web properties; (ii) a Laboratory Information M ...]]	
MacroGenics-Gilead Collaboration-and-License 2022-10-14	NOT_IDENTIFIABLE_AS_AI	[[1.86 "MacroGenics Platform" means MacroGenics' proprietary DART® and TRIDENT® platforms regardless of application, each as further described in Schedule 1.86 (M ...]]	
MayoFoundation-ViewpointMolecular Know-How-License 2022-01-24	NOT_DRUG_DISCOVERY	[[“Field”: the treatment, diagnosis or prevention of any cancer in humans or animals by utilizing any Medical Information Technology directly or	

excluded folder	disposition	basis (deciding span first)	obs
		indirectly in con ...]]	
Maze-Shionogi License 2024-03-27	NOT_IDENTIFIABLE_AS_AI	[[1.131 “Maze Platform” means Maze’s proprietary platform known as the “Maze Compass™” platform, which consists of [***].]]	
Merus-Gilead Collaboration- Option-and-License 2024-03-05	NOT_IDENTIFIABLE_AS_AI	[[“Merus Platform Technology” means Merus’s proprietary: (a) Triclonics® [***]; (b) [***]; (c) [***]; (d) [***]; (e) technology [***]; (f) [***]; and (g) [***]. F ...]]	
NanjingLeads- Dianthus License- and-Collaboration 2025-10-16	NOT_IDENTIFIABLE_AS_AI	[[1.103 “Licensed BDCA2 Linker Know-How” means any Licensed Know-How related to ([***]]	
NanyangTechnologi cal-Nanyang Intellectual- Property- Assignment 2025- 11-27	NOT_ALLIANCE:asset_purchase	[[Assignor hereby agrees to assign all its rights, titles and interests in and to the intellectual property rights to the	

excluded folder	disposition	basis (deciding span first)	obs
NextCure-HainanSimcere License 2025-06-13	NOT_AI	Inventions and the Patents (as hereinaft ...] [(ffff) “Zaiming ADC Platform Technology” means the ADC technology Controlled by Zaiming as described in Schedule 1.1(ffff). For clarity, the Zaiming ADC Platfor ...]	
NisshinboMicro-Ainos-TaiwanInabata Co-Development 2023-08-09	NOT_ALLIANCE:services	[[with respect to the transaction that NISD outsources the Development (as defined below) to Ainos.]]	
Novartis-MolecularPartners License-and-Collaboration 2021-12-13	NOT_AI	[[“Platform” means Licensor’s proprietary DARPin Binding Domain platform technology, pursuant to which Licensor produces pharmaceutical product candidates, includ ...]]	
Novartis-MonteRosa License 2024-10-25	NOT_DRUG_DISCOVERY	[[WHEREAS, Licensor owns or otherwise	

excluded folder	disposition	basis (deciding span first)	obs
		Controls certain Patent Rights and Know-How related to the Licensed Compounds;	
		WHEREAS, subject to the terms and conditions ...]]	
NovoNordisk-Septerna Collaboration-and-License 2025-05-13	NOT_IDENTIFIABLE_AS_AI	[[1.131 “Septerna Platform” means [***].]]	
Oncotelic-TechforceRobotics Joint-Development-Manufacturing-and-Licensing 2026-03-31	NOT_DRUG_DISCOVERY	[[WHEREAS, the Parties desire to combine Oncotelic’s AI platform and pharmaceutical expertise with TechForce’s robotics and hardware capabilities to develop, manu ...]]	
Onotelic-GoldenMountain Research-and-Services 2020-02-03	NOT_DRUG_DISCOVERY	[[AI/Supercomputing team: a. Deliverable: build AI model around #infection, #mortality,#cure to define the best predictive model of disease progression. This will ...]]	
Parabilis-Regeneron License-and-	NOT_IDENTIFIABLE_AS_AI	[[1.148 “Parabilis	

excluded folder	disposition	basis (deciding span first)	obs
Collaboration 2026-05-15		Platform Technology” means [***].]]	
Paragon-Viridian Amended-and-Restated-License 2024-09-20	NOT_AI	[[A.Pursuant to that certain Antibody Discovery and Option Agreement entered into by and between the Parties, dated January 19, 2022, as amended by that certain F ...]]	
Pegasos-TempusAi Intellectual-Property-License 2024-05-18	NOT_DRUG_DISCOVERY	[[1.13 “Field” means the diagnosis, prevention, treatment, prophylaxis, management or cure of disease or disability in humans or other healthcare-related initiati ...]]	
Pieris-BpAsset Exclusive-Product-License 2021-04-24	NOT_AI	[[“Pieris Platform Technology” means (i) Anticalin Libraries, Anticalin Selection, Anticalin Expression, Anticalin Characterizatio	

excluded folder	disposition	basis (deciding span first)	obs
		n, and Anticalin Affinity Matura ...]]	
PrimeMedicine-Juno Research-Collaboration-and-License 2024-09-28	NOT_IDENTIFIABLE_AS_AI	[[1.182“Prime Platform” means [***]. For purposes of this Agreement, Prime Platform does not include [***].]]	
Prothena-CelgeneSwitzerland Global-License 2023-07-05	NOT_IDENTIFIABLE_AS_AI	[[1.65 “Prothena Platform Technology” means [***], which shall [***]; but in any case excluding [***].]]	
Prothena-CelgeneSwitzerland U-S-License 2021-07-30	NOT_IDENTIFIABLE_AS_AI	[[1.66“Prothena Platform Technology” means the [***]; but in any case excluding [***].]]	
Prothena-CelgeneSwitzerland letter-agreements-amending-the-Master-Collaboration 2024-01-16	NOT_ALLIANCE:instrument_of_other_alliance	[[Reference is made to the Master Collaboration Agreement between Prothena Biosciences Limited, an Irish private limited company (hereinafter “Prothena”), and Cel ...]]	
Raphael-AIcreatesAI Enterprise-Ai-Transformation-	NOT_ALLIANCE:services	[[ENTERPRISE AI TRANSFORMAT	

excluded folder	disposition	basis (deciding span first)	obs
Growth- Partnership-Annual- Managed 2026-07-30		ION & GROWTH PARTNERSHIP ANNUAL MANAGED SERVICES PROPOSAL AND AGREEMENT]]	
RayzeBio-Blaze Discovery-and- License 2021-02-22	NOT_IDENTIFIABLE_AS_AI	[[1.14 “Blaze Platform Know How” means any Know How (other than Patents) related to the CDP discovery platform Controlled by Blaze as of the Effective Date, inclu ...]]	
RayzeBio- PeptiDream License-and- Research- Collaboration 2020-08-03	NOT_IDENTIFIABLE_AS_AI	[[“PeptiDream PDPS Platform Technology” means (a) all Know-How and Patent Rights that are (i) Controlled by PeptiDream or its Affiliates as of the Effective Date, ...]]	
RayzeBio- PeptiDream License-and- Research- Collaboration 2020-08-04	NOT_IDENTIFIABLE_AS_AI	[[“PeptiDream PDPS Platform Technology” means (a) all Know-How and Patent Rights that are (i) Controlled by PeptiDream or its Affiliates as of the Effective	

excluded folder	disposition	basis (deciding span first)	obs
Roche-FoundationMedicine Collaboration XXXX-XX-XX	COMMENCED_UNKNOWN_PRE2020	Date, ...]] no quotable text (D1 rule NOT_PRINTED)	
Roche-Remix Research- Collaboration-and- License 2023-12-21	NOT_IDENTIFIABLE_AS_AI	[[1.87 Remix Platform Technology [***]]]	
SanofiUs- DarioHealth Exclusive- Preferred-Partner- Co-Promotion- Development- Collaboration 2022- 02-28	NOT_DRUG_DISCOVERY	[[WHEREAS, Dario is a digital therapy technology company which has developed and commercializes a mobile and web-based, customized, user-centric, modular platform ...]]	
Scribe-Genzyme License 2023-06-19	NOT_AI	[[WHEREAS, Scribe is a biotechnology company that has certain expertise and proprietary rights relating to a next- generation gene editing platform (CRISPR/CasXE) ;]]	
Seagen-Lava Exclusive-License 2022-09-23	NOT_IDENTIFIABLE_AS_AI	[[1.111“Lava Platform” [***]. 1.112“Lava Platform Improvement” has the meaning	

excluded folder	disposition	basis (deciding span first)	obs
Seagen-ZaiLab Collaboration-and-License 2022-09-20	NOT_IDENTIFIABLE_AS_AI	set forth in Section 10.1.1.]] [[1.138 “Seagen Platform” shall mean Seagen’s proprietary antibody-drug conjugate platform (i) generally relating to [***] and (ii) not solely and specifically re ...]]	
Senti-Bluerock Collaboration-and-Option 2021-05-21	NOT_IDENTIFIABLE_AS_AI	[[1.93 “Senti Platform” means [***].]]	
Senti-Spark Research-Collaboration-and-License 2021-04-09	NOT_IDENTIFIABLE_AS_AI	[[1.72 “Senti Platform” means Patent Rights and Know-How that are [***] and are [***]. For clarity, the Senti Platform [***].]]	
ShanghaiEpimab-Fl2024005 License-and-Collaboration 2024-08-05	NOT_IDENTIFIABLE_AS_AI	[[1.30 “FIT-Ig Technology” means EpimAb’s proprietary technology platform for the development of bi-specific antibodies, [***], including associated Patents and K ...]]	
SichuanKelun-Crescent License-	NOT_AI	[[Whereas, SKB is a	

excluded folder	disposition	basis (deciding span first)	obs
and-Collaboration 2025-12-02		biotechnology company with a proprietary antibody-drug-conjugate platform that has developed SKB Know-How and has rights to SKB Patents (each, ...]]	
Stoke-Biogen License-and- Collaboration 2025- 02-14	NOT_IDENTIFIABLE_AS_AI	[[“Stoke Platform” means [***]. Section 1.178 “Stoke Platform Improvement Know-How” means all Arising Know-How discovered, invented, developed or otherwise made b ...]]	
TScan-Amgen Research- Collaboration-and- License 2023-05-08	NOT_IDENTIFIABLE_AS_AI (ADJ-1)	[[Whereas, TScan is a biotechnology company and has licensed and further developed a technology to perform a genome-wide screening platform to identify antigens r ...]]	
Tempus-PathosAi Master 2021-08-19	DATA_OR_SERVICES_ONLY	[[Data. In service of Tempus’ mission to	

excluded folder	disposition	basis (deciding span first)	obs
		advance precision medicine, Tempus makes use of de-identified data to facilitate innovation in therapies and patient care ...]]	
Tempus-Recurion Master 2023-11-03	DATA_OR_SERVICES_ONLY	[[Permitted Uses include Client's use of Licensed Data for Client to develop, train, improve, modify, and create derivative works of Client's and its Affiliates' ...]]	
Tempus-Remix Master 2023-08-16	DATA_OR_SERVICES_ONLY	[[any aggregated or otherwise de-identified data stored in Tempus' technology platform is not Client's Confidential Information under this Agreement.]]	
TempusAi-Pegasos Data-License 2024-05-18	DATA_OR_SERVICES_ONLY	[[“Tempus Platform” means the proprietary real world data libraries and associated systems and technology	

excluded folder	disposition	basis (deciding span first)	obs
Titan-Indegene Agreement-for-Co-Promotion-Partnership 2020-06-23	NOT_ALLIANCE:co-promotion	owned by Tempus.]] [[AGREEMENT FOR CO-PROMOTION PARTNERSHIP This Agreement For Co-Promotion partnership (this “Agreement”), is made as of June 23, 2020 (the “Effective Date”)]]	
Tscan-Novartis Collaboration-and-License 2020-03-27	NOT_IDENTIFIABLE_AS_AI	[[1.140. “TScan Background Platform IP” shall mean all Patents and Know-How Controlled by TScan as of the Effective Date relating directly to the technology descr ...]]	
Vir-Astellas Collaboration-and-License 2026-02-19	NOT_AI	[[1.11.“Amunix Platform” has the meaning set forth on Schedule 1 (Terms Defined in the Sanofi License).]]	
Voronoi-Brickell License-and-Development 2021-08-27	NOT_IDENTIFIABLE_AS_AI	[[“[***] Platform” means [***], a description of which is set	

excluded folder	disposition	basis (deciding span first)	ob s
		forth in Exhibit E.]]	
XilioDevelopment-AbbVie Collaboration-License-and-Option 2025-02-10	NOT_IDENTIFIABLE_AS_AI	[[1.297. “Xilio Platform Technology” means [**].]]	
Xyphos-Poseida Collaboration-and-License 2024-04-30	NOT_IDENTIFIABLE_AS_AI	[[1.4 “ACCEL Platform” means [***].]]	
Yumanity-MSD Exclusive-License-and-Research- Collaboration 2020-06-19	NOT_IDENTIFIABLE_AS_AI	[[“Company Platform” means the Company’s drug discovery platform consisting of [***].]]	
Zymeworks-Atreca Option-and-License 2022-04-04	NOT_AI	[[A.Zymeworks controls a proprietary conjugation, linker, and cytotoxic payload platform, which is known as ZymeLink™, for developing pharmaceutical drug-conjugat ...]]	
gilead-Gritstone Collaboration- Option-and-License 2021-01-29	NOT_IDENTIFIABLE_AS_AI	[[1.66. “EDGE™ Machine-Learning Platform Technology” means the [**].]]	
inVentivCommercial-Agile Project 2020-04-30	NOT_ALLIANCE:services	[[A. Client and Syneos Health have entered into a Master	

excluded folder	disposition	basis (deciding span first)	obs
		Service Agreement dated as of October 11, 2017 (the "MSA"). B. Client and Syneos Health desire to enter ...]]	

1 coded alliance(s) pass the Step-1 AI test only on 'software'/'databases' in the platform's own definition (ai_basis_rule; marked (S): Genmab-EbumabHemophilia DuoBody-License 2020-04-01). Without them the verdicts are: CORRESPONDS 15, FIT_UNDETERMINED 1, NO_CORRESPONDENCE 3, NO_PROVISION 2, PARTIAL 7, UNDETERMINED 17.

Distribution of improvement categories

The 38 coded alliances carry 39 platform allocations and 46 branches; 7 allocations are HYBRID, split by subject matter or by a time trigger in the text (codebook §4.4, CB-5c).

distribution in this cohort. UNDETERMINED and ABSENT are shown beside the coded counts and are never folded into each other.

code	I.P name	branches	of which FIT UNDETERMINED	alliances holding it	I.P share (context only*)
1	Assign Improvements	10	0	10	32%
2	Assign & License	6	0	6	20%
3	License (to partner)	2	0	2	14%
4	License with grant-back	1	0	1	18%
5	Joint / each owns its sole	3	0	3	16%
OTHER:ALL_JOINT	–	1	0	1	–
OTHER:ASSIGN_TO_PARTNER	–	4	1	4	–
UNDETERMINED	–	17	0	14	–

code	I.P name	branches	of which FIT UNDETERMINED	alliances holding it	I.P share (context only*)
ABSENT	–	2	0	2	–

* Shares as reported in the I.P article for the analysis of improvement provisions it cites. The article does not state that analysis's population or period, so the shares are context only; no test against them is made.

Correspondence with the ADC categories

Verdicts are computed per branch by `analyze_codes.verdict` against the codes observed in the Q-ADC cohort (1, 2, 3, 4, OTHER:ALL_JOINT, OTHER:ASSIGN_TO_PARTNER, OTHER:PARTNER_SOLE_JOINT): CORRESPONDS 16, FIT_UNDETERMINED 1, NO_CORRESPONDENCE 3, NO_PROVISION 2, PARTIAL 7, UNDETERMINED 17.

- NO_CORRESPONDENCE (IP5_NOT_OBSERVED_IN_ADC) — first instance Aum-Newsoara Discovery-and-Co-Development-Collaboration 2020-11-02, the INVENT_BASIS element: [[8.1.1. Ownership of Technology. Each Party shall own any Invention made solely by its employees, agents or contractors in connection with the performance of this Agreement and all intellectual property rights therein. The Parties ...]]

Sensitivity of the verdicts (allocations whose verdict changes, of 39): tie-break CB-5b (grant-back without licence read as 5): 0; comparator without 1 (held by one Q-ADC alliance): 10; comparator without 3 (held by one Q-ADC alliance): 2; comparator without OTHER:PARTNER_SOLE_JOINT (held by one Q-ADC alliance): 0.

The training term

Of the 38 coded alliances, 24 state a right to use partner data to train or improve the platform, or a restriction reaching that data (CB-6b, CB-6c); 8 have that element redacted; 6 say nothing about it. Of those 6, 2 have no allocation provision at all (ABSENT), 0 are UNDETERMINED in every branch, and 4 carry a coded improvement allocation with no visible training term.

Recorded sensitivity D1 (Mark ruling R3c-4: kept as coded; ExscientiaAi-MerckHealthcare Research-Collaboration 2023-09-19): Exscientia-Merck's TR is PROHIBITED on the visible 9.4.1 covenant (the platform must prevent incorporation of Merck Background IP), which refers to a wholly redacted Schedule 9.4.1 ('as described in'); the reading TR=REDACTED is shown here. Under that reading the split is 23 / 9 / 6 (explicit / redacted / silent).

- R3c-4: Exscientia-Merck: TR PROHIBITED is kept on the visible 9.4.1 covenant (the platform must prevent incorporation of Merck Background IP); the wholly redacted Schedule 9.4.1 describes how, and cannot reverse the visible prevention. The reading TR=REDACTED is disclosed as a recorded sensitivity of the training-term counts.

- R3c-5: Sanofi-Valo (both licences): TR PERMITTED_LIMITED is kept. The visible permission is 1.31 ('The term "Development" includes the use of advanced machine learning algorithms and data analysis') read with the 2.1 licence to use the Other Data to Exploit the Licensed Compounds; 2.14 limits it to those compounds. CB-7e's record for Sanofi-Valo is corrected to cite these words.

The OP-21-01 shape test and its disclosure

Rule (codebook CB-4, recorded after coding and before this result was computed): Shape B if the coded Q-DT branches carry two or more distinct structural codes, Shape A if they carry one and vary only in presence or parameters. The coded branches carry 7 distinct structures (1, 2, 3, 4, 5, OTHER:ALL_JOINT, OTHER:ASSIGN_TO_PARTNER), so the result is Shape B. Restricted to the 24 alliances with an explicit training term, they carry 7 (1, 2, 3, 4, 5, OTHER:ALL_JOINT, OTHER:ASSIGN_TO_PARTNER).

Disclosure: before screening, Mark pre-registered (OP-21-01, data_training topic.json amendment 1) that the harvest would take one of two shapes, A or B; the amendment does not say which he expected. SESSION_STATE records that an early, non-analytical read of 3 contracts suggested Shape B. The result is consistent with that early read. An agreeing result is not evidence of independence, the decision rule was written after the codes were visible, and a five-category codebook makes structural variety easy to register.

Before 2020: the pre-registered PRE2020 check

The PRE2020 check (protocol analyze/PRE2020_PROTOCOL.md, committed before any pre-2020 text was read; result analyze/pre2020/result.json) covers the 193 harvested data_training folders dated before 2020. 70 carry no computational term (Stage A, a lexical screen and therefore a lower bound on early clauses); 123 were read under the same Step-1 and training-term tests as this cohort, 49 of them by a second reader. Its pre-registered decision on the word 'newest' is NOT_SUPPORTED under every resolution of the two readers' disagreements.

PRE2020 measures under each resolution, computed by scripts/analyze_pre2020.py from the reader files.

resolution	earliest explicit training term (instrument date)	alliances with one before 2016	before 2020	≤2009 (explicit / coded in)	2010–2014	2015–2019
reader A only	2000-11-22 Genaissance-Janssen Hap2000 2000-11-22 (PERMITTED_LIMITED)	24	30	14 / 26	8 / 10	8 / 16
reader B where read	1997-09-02 SmithklineBeecham-Incyte-Diadexus Collaboration-and-License 1997-09-02 (PERMITTED_LIMITED)	25	32	17 / 27	7 / 9	8 / 15

resolution	earliest explicit training term (instrument date)	alliances with one before 2016	before 2020	≤2009 (explicit / coded in)	2010–2014	2015–2019
both readers agree	2000-11-22 Genaissance-Janssen Hap2000 2000-11-22 (PERMITTED_LIMITED)	22	28	14 / 24	7 / 9	7 / 14

Descriptive only (not pre-registered; never decides the verdict; reader B's tag, so folders B did not read are not tagged): the earliest explicit training terms that name training or a model are SmithklineBeecham-Incyte-Diadexus Collaboration-and-License 1997-09-02 (1997-09-02); Genaissance-Janssen Hap2000 2000-11-22 (2000-11-22); StructuralGenomix-EliLilly Collaboration-and-License 2003-04-14 (2003-04-14); Cytokinetics-AstraZenecaAb Collaboration-and-License 2003-12-15 (2003-12-15); Upstream-UniversityOf-VancouverCoastal Collaborative-Research 2004-05-01 (2004-08-11).

PRE2020 limit: Stage A is a lexical screen: a computational alliance whose texts use none of the regex terms is missed (lower bound on early clauses). PRE2020 limit: Statements are about this harvested filed record (FOIA-era and later exhibits), never about contracts outside it. PRE2020 limit: CB-6c counts a 'solely to perform' data licence as PROHIBITED; most early PROHIBITED rows rest on that rule, not on a clause naming training.

For comparison, 24 of the 38 coded alliances dated 2020 or later state an explicit training term. The two periods' filed records differ in coverage (FOIA-era exhibits before, IPO and periodic-report exhibits after), so the comparison is context, not a trend test.

Protective measures

protective measures over the 38 coded alliances, by the strongest status any allocation carries. Counts are of visible text; a redacted clause is shown as such, never as absent.

measure	present	redacted only	general clause only	none found
SEG	16	2	0	20
NC	26	2	0	10
SECURE_ENV	15	2	21	0
DATA_SEG	15	0	0	23
NON_USE	31	2	5	0
DELETION	17	0	15	6

- R3c-2: NC visible-activity test, applied uniformly: a non-compete is PRESENT only where the restricted activity itself is visible in the covenant. Where the activity is under a marker and can be inferred only from an exception, carve-out, caption, cross-reference or definition, it is REDACTED_ONLY. (folders changed here: ImmunoGen-HangzhouZhongmei Collaboration-and-License 2020-10-19)

- R3c-6: R3c-2 re-sweep of the data_training NC statuses: all 27 PRESENT rows have a visible restricted activity (CB-6e: activity visible, field redacted = PRESENT); no status changes. Immunome-AbbVie 8.1.1 and Exscientia-Sanofi 2.1 confirmed PRESENT.
- R3c-7: A restriction on dealing in specific co-owned or optioned IP (a no-shop or co-owner licensing bar) is not a non-compete under CB-6e; Lieber's reading is applied to Nanyang: NC PRESENT -> ABSENT. (folders changed here: NanyangTechnological-Nanyang Research-Collaboration 2025-11-01)
- R3c-8: MSD-Evaxion: NON_USE GENERIC -> PRESENT; 4.3(i) is a specific use bar, not a general confidentiality clause (CB-6a). (folders changed here: MSD-Evaxion Option-and-License 2024-09-25)

Reading notes

An alliance is counted under a code if any of its branches computes to it, whether the fit is EXACT or PARTIAL (a named element met only by silence or default; the per-alliance table names it). Alliances that hold a code only as a PARTIAL fit: code 1: 2 (Sanofi-ValoHealth License 2021-02-08, Sanofi-ValoHealth License 2021-05-10); code 2: 2 (LieberInstitute-BullFrogAi Data-Use-and-Technology-Partnership 2023-09-07, RubrYc-iBio Collaboration-and-License 2021-08-23); code 3: 2 (KalaBio-2624465Ontario Platform-Development-and-Exclusive-License 2026-03-03, KronosBio-Genentech Collaboration-and-License 2023-01-06); code 4: 0; code 5: 0.

Codes 3, 4 and 5 share one ownership test: ownership follows inventorship. They differ in the licence to the partner and the grant-back (codebook primary codes). Of the 1 alliances holding code 4, 1 have a code-4 branch whose ownership elements also meet code 5's ownership test (expressly or by silence); they are code 4, not 5, because the originator's improvements are licensed to the partner and the partner grants rights back.

1 alliance(s) are coded from both sides, each party being the platform originator of one allocation: GSK-Tempus Strategic-Collaboration 2022-08-01. Each such alliance counts once under every code either allocation carries.

- R3c-3: Schrodinger-Novartis: a caption cannot bound the reach of an omitted controlling schedule where the agreement disclaims captions (17.16). The improvement allocation collapses to one UNDETERMINED branch (O_PS, O_J, O_OS, L_P, GB REDACTED under CB-1 / CB-6d). (folders changed here: Schrödinger-Novartis Research-Collaboration-and-License 2024-11-11)

The comparator's dependency on CB-6f

CB-6f sensitivity (codebook CB-6x, recorded after the reads that applied it): on the strict, definition-only reading (3 branches recomputed with no licence to the partner:

JiangsuAlphamab-ArriVent Research-and-Collaboration 2024-06-02 branch 0 2 EXACT → 1 EXACT; JiangsuAlphamab-ArriVent Research-and-Collaboration 2024-06-02 branch 2 4 EXACT → 4 PARTIAL(L_P=NONE); Sutro-Ipsen Exclusive-License 2024-03-29 branch 1 4

EXACT → 4 PARTIAL(L_P=NONE)) the Q-ADC comparator is 1, 2, 3, 4, OTHER:ALL_JOINT, OTHER:ASSIGN_TO_PARTNER, OTHER:PARTNER_SOLE_JOINT and 0 allocation verdicts change. Combined with the alternative CB-5b tie-break the comparator is 1, 2, 3, 4, 5, OTHER:ALL_JOINT, OTHER:ASSIGN_TO_PARTNER, OTHER:PARTNER_SOLE_JOINT and 3 change (Aum-Newsoara Discovery-and-Co-Development-Collaboration 2020-11-02: NO_CORRESPONDENCE(IP5_NOT_OBSERVED_IN_ADC) → CORRESPONDS(5); Exscientia-BMS Collaboration-and-License 2021-05-03: NO_CORRESPONDENCE(IP5_NOT_OBSERVED_IN_ADC) → CORRESPONDS(5); Roche-MonteRosa Collaboration-and-License 2023-10-16: NO_CORRESPONDENCE(IP5_NOT_OBSERVED_IN_ADC) → CORRESPONDS(5)). Under the strict reading the single-alliance comparator codes are 3, OTHER:PARTNER_SOLE_JOINT; comparator without 3: 2; comparator without OTHER:PARTNER_SOLE_JOINT: 0.

Codebook rulings and their ratification status

Codebook v1 was recorded before Analyze coding (no provision had been coded). Amendments follow, each with the timing it records (rendered from analyze/codebook.json) and its status; Mark's ruling A8 ratified ADJ-1, CB-5, CB-6, CB-6x; Mark's ruling R3c-1 ratified CB-7a, CB-7b, CB-7c, CB-7d, CB-7e, CB-7f, CB-7g, CB-7h, CB-7i.

codebook amendments and timing

amendment	version	type	recorded	status
CB-1	v1.1	interpretation (no new label)	before: the main coding pass; after a 2-folder pilot (Sutro-Astellas, BioAtla-Himalaya) whose reader output is set aside and re-coded under this amendment	no ratification recorded
CB-2.1	v1.2	new OTHER label	after reader A coding (labels are created on first instance, codebook residual_codes rule); quote cut by code from the provision's offsets	no ratification recorded
CB-2.2	v1.2	new OTHER label	after reader A coding (labels are created on first instance, codebook residual_codes rule);	no ratification recorded

amendment	version	type	recorded	status
			quote cut by code from the provision's offsets	
CB-2.3	v1.2	new OTHER label	after reader A coding (labels are created on first instance, codebook residual_codes rule); quote cut by code from the provision's offsets	no ratification recorded
CB-2.4	v1.2	new OTHER label	after reader A coding (labels are created on first instance, codebook residual_codes rule); quote cut by code from the provision's offsets	no ratification recorded
CB-2	v1.2	compute rule (scripts/analyze_codes.py)	after reader A coding, before reader B and before any verdict was computed	no ratification recorded
CB-3	v1.3	compute fix (scripts/analyze_codes.py) to match the codebook's own FIT definition	after readers A and B and the adjudicator, before any Q-DT verdict was computed; raised by the adjudicator (Mayo-Sorrento). Readers record elements, not FIT, so no read changes.	no ratification recorded
ADJ-1	v1.3	adjudication rule (scripts/analyze_finalize_reads.py)	(timing stated in its type)	ratified by Mark (A8)
CB-4	v1.3	shape-test decision rule (OP-21-01)	after coding was complete and code distributions were visible, before the Q-DT verdicts and shape result were computed	no ratification recorded

amendment	version	type	recorded	status
			by scripts/analyze_report.py; the report discloses this timing.	
CB-5	v1.4	clarifications raised by R3 (recorded after R3, before the R3 fix pass)	(timing stated in its type)	ratified by Mark (A8)
CB-6	v1.4	secondary-code and TR visibility rule (raised by R3)	(timing stated in its type)	ratified by Mark (A8)
CB-6x	v1.5	rulings applied by the R3 fix-pass adjudicators (ADJ2/SEC), recorded by the lead AFTER those reads were written; they ratify and harmonise readings, and the report discloses this timing	(timing stated in its type)	ratified by Mark (A8); recorded after the reads that applied it, which stays disclosed
MARK-AN	v1.6	operator rulings (Mark) on analyze/MARK_QUESTIONS_analyze.md; source analyze/MARK_RULINGS_analyze_2026-10-11.json	(timing stated in its type)	operator ruling (Mark)
CB-7	v1.6	lead rulings from the R3b review, recorded AFTER the reads they correct (ADJ3 applies them); NOT yet ratified by Mark; the report discloses timing and lists each for ratification	(timing stated in its type)	ratified by Mark (R3c-1: CB-7a-i); recorded after the reads that applied it, which stays disclosed
MARK-R3c	v1.7	operator rulings (Mark, 2026-10-13) after the R3c fresh check; source analyze/MARK_RULINGS_analyze_	(timing stated in its type)	operator ruling (Mark)

amendment	version	type	recorded	status
		2026-10-13.json		
MARK-R3c-DT	v1.8	operator rulings (Mark, 2026-10-13, Article 22 session) on the open data_training R3c findings; source analyze/MARK_RULINGS_analyze_2026-10-13.json R3c-3..R3c-10; applied by the ADJ5 (complete read) and ADJ4 (status) layers	(timing stated in its type)	operator ruling (Mark)

Folders whose adjudication entries (ADJ3, ADJ4) cite each CB-7 rule, whether or not the rule changed the read: CB-7c: 1 (Codexis-ShireHuman Strategic-Collaboration-and-License 2020-03-23); CB-7d: 1 (KronosBio-Genentech Collaboration-and-License 2023-01-06); CB-7e: 3 (Codexis-ShireHuman Strategic-Collaboration-and-License 2020-03-23, Sanofi-ValoHealth License 2021-02-08, Sanofi-ValoHealth License 2021-05-10); CB-7f: 24 (Adimab-Adagio Collaboration 2021-05-21, Aum-Newsoara Discovery-and-Co-Development-Collaboration 2020-11-02, Codexis-ShireHuman Strategic-Collaboration-and-License 2020-03-23, Exscientia-BMS Collaboration-and-License 2021-05-03, Genmab-EbumabHemophilia DuoBody-License 2020-04-01, Iambic-HLundbeck Collaboration-and-Option 2024-09-23, ImmaticsBiotechnologies-Moderna Master-Collaboration-and-License 2023-09-07, Immunome-AbbVie Collaboration-and-Option 2023-01-04, KronosBio-Genentech Collaboration-and-License 2023-01-06, MSD-Evaxion Option-and-License 2024-09-25, NanyangTechnological-Nanyang Research-Collaboration 2025-11-01, NanyangTechnological-NybAi License 2025-03-01, NexImmune-ZephyrAi Joint-Research 2022-03-16, Novartis-MonteRosa Collaboration-Option-and-License 2025-09-13, RayzeBio-Nimble Research-Collaboration-and-License 2021-02-08, Roche-MonteRosa Collaboration-and-License 2023-10-16, RubrYc-iBio Collaboration-and-License 2021-08-23, Schrodinger-AconcaguaBio Collaboration 2023-11-07, Schrodinger-BMS Collaboration-and-License 2020-11-22, Schrodinger-LhotseBio Collaboration 2020-10-09, StatensSerum-Evaxion CAF09b-Supply-Patent-Know-How-Trademark-Licence 2020-11-30, Sybleu-DyoBiotechnologies Agreement-By-and-Between-Sybleu-Inc-and-Agreement 2023-06-26, Terray-Odyssey Collaboration-and-License 2024-09-11, YuvaBio-Northstrive Development-and-License 2025-04-09). CB-7c is applied by `analyze_codes.compute_branch` to every branch: 1 branch(es) in 1 alliance(s) are counted under a code whose FIT depends on hidden words (Codexis-ShireHuman Strategic-Collaboration-and-License 2020-03-23).

- R3c-9: S1-S3 stay open. Cohort unchanged: RayzeBio-Nimble, Kronos-Genentech, Schrodinger-BMS and Genmab-Ebumab ((S), software/databases only) stay in. The Sanofi-Valo O_J reading is disclosed as an open reading for data_training, and the unread Immatics Exhibit C in the Limits line on unread instruments.

Open readings and their effect on the counts

- S4 (R3-DT-RC0-10 / older question for Mark (kept open by ruling R3c-9); Sanofi-ValoHealth License 2021-02-08; Sanofi-ValoHealth License 2021-05-10): Sanofi-

alliance counts as coded and under each open reading taken alone, recomputed by compute_branch; a changed count shows the as-coded value beside it. These readings are open questions for Mark, not results.

r e a d i n g	c	c	c	c	c	A	ASSI	TE	with an UN DE	fu ll y pl	has pl it (H Y B RI	bran ch e s P A R T I A L	bran ches NO_C ORR ESP OND ENC	bran ches FIT_ UND ETE RMI NED	bran ch es UN DE RM INE D	bran ch es NO _P RO VIS IO N	T R E D A C T E D	T R E A C T E D	
	1	2	3	4	5	T	R	nch	e	n	S	L	E	NED	D	N	it	D	
a s c o d e d	1 0	6	2	1	3	1	4	14	2 4	7	16	7	3	1	17	2	2 4	8	6
S 4	1 0	6	2	1	3	1	4	14	2 4	7	18 (as co de d 16)	5 (a s c o d e d 7)	3	1	17	2	2 4	8	6

Lake witness leg

The PLAN §4.1 lake witness leg (protocol analyze/lake_leg/PROTOCOL.md, result analyze/lake_leg/data_training.json) compared the filed bytes of each of this topic's 299 distinct harvested exhibit versions (299 folder-versions in 152 candidate folders) with the lake's stored copy at lake snapshots 280174, 280268, 280294 (more than one snapshot answered; each row records its own): EQUAL 154, WITNESS_CONFLICT 14, NOT_IN_LAKE 131, UNMEASURED 0. NOT_IN_LAKE by reason class (derived from each version's own form, exhibit type and filing date): after_lake_end 13, form_not_held 106, exhibit_type_not_ex10 0, 8k_known_hole_2018_2021 0, unexplained 12. Unexplained absences: MacroGenics-Gilead Collaboration-and-License 2022-10-14 [0001125345-23-000059:a1022_gileadcollab.htm]; MayoFoundation-ViewpointMolecular Know-How-License 2022-01-24 [0001437749-23-014658:ex_520391.htm]; Schrodinger-BMS Collaboration-and-License 2020-11-22 [0001490978-23-000024:sdgr-20221231exx10irstamen.htm]; Schrödinger-Novartis Research-Collaboration-and-License 2024-11-11 [0001490978-25-000014:sdgr-20241231exx1048novar.htm]; Oncotelic-TechforceRobotics Joint-Development-Manufacturing-and-Licensing 2026-03-31 [0001493152-26-015242:ex10-1.htm]; Pieris-BpAsset Exclusive-Product-License 2021-04-24 [0001583648-21-000034:pieris-bpexclusiveproduc.htm]; Genentech-Pieris Research-Collaboration-and-License 2021-05-19 [0001583648-21-000034:pieris-genentechcollabor.htm]; Paragon-Viridian Amended-and-Restated-License 2024-09-20 [0001590750-24-000023:viridian-paragonamendedand.htm]; BristolMyers-Avidity Research-Collaboration-and-License 2023-11-27 [0001599901-24-000025:avidity-bmsxresearchcollab.htm]; Seagen-ZaiLab Collaboration-and-License 2022-09-20 [0001628280-22-029246:zlab-20220930exx101_seage.htm]; NisshinboMicro-Ainos-TaiwanInabata Co-Development 2023-08-09 [0001654954-23-014023:aimd_ex101.htm]; IntegralMolecular-Context Research-Collaboration-and-License 2021-04-06 [0001842952-23-000041:amendment1tointegralcollab.htm]. UNMEASURED: none (by cause: query_error 0, no_lake_hash 0). Witness conflicts: AstrazenecaAb-Tempus Master-Services 2021-11-17 [0001193125-24-142956:d221145dex1016.htm]; GSK-Tempus Strategic-Collaboration 2022-08-01 [0001193125-24-142956:d221145dex1018.htm]; Tempus-Recursion Master 2023-11-03 [0001193125-24-142956:d221145dex1022.htm]; AstrazenecaAb-Tempus Master-Services 2021-11-17 [0001193125-24-142956:d221145dex1024.htm]; AstrazenecaAb-Tempus Master-Services 2021-11-17 [0001193125-24-142956:d221145dex1025.htm]; AstrazenecaAb-Tempus Master-Services 2021-11-17 [0001193125-24-142956:d221145dex1026.htm]; Scribe-Genzyme License 2023-06-19 [0001193125-26-294804:d21355dex1013.htm]; Alcon-RxSight License-Collaboration-and-Development 2026-06-30 [0001193125-26-335153:rxst-ex10_3.htm]; CytomX-Regeneron Collaboration-and-License 2022-11-16 [0001193125-26-337950:ctmx-ex10_3.htm]; CytomX-Regeneron Collaboration-and-License 2022-11-16 [0001193125-26-337950:ctmx-ex10_4.htm]; Codexis-ShireHuman Strategic-Collaboration-and-License 2020-03-23 [0001200375-20-000020:exhibit101q120.htm]; GatesVentures-Schrodinger Independent-Contractor 2020-06-23 [0001490978-26-000068:sdgr-20260630x10xqex104gat.htm]; Amunix-Vir License 2024-07-31 [0001628280-26-053549:a20260630-q2ex101xsanofi_v.htm]; Allogene-AllogeneOverland Exclusive-License

2020-12-14 [0001628280-26-056213:allo-20260630xex101.htm]. In 14 of these 14, the lake's copy carries a sec.gov bot-manager script tag and equals the filed bytes once that tag is removed; that is a diagnostic and the status stays WITNESS_CONFLICT (analyze/lake_leg/WITNESS_CONFLICTS_for_Mark.md). EQUAL means only that the lake's copy and the harvested copy are byte-identical; this leg does not measure completeness and is not a statement that Harvest or Analyze is complete.

Limits

Codes describe what the filed text allocates. They are candidate generation and structural description, not a view on enforceability, recorded ownership, or what an unredacted copy says, and not a freedom-to-operate view.

Redaction is not absence: UNDETERMINED means the deciding words are under a redaction marker or in an unfiled instrument the text says governs (codebook CB-1, CB-6d), and it is reported beside every count.

Every count here is of this cohort of filed exhibits; nothing here describes alliances outside it.

No patent claim scoring (KC) was used in this analysis, and nothing here asserts the strength of any patent claim.

3 coded alliance(s) record 5 instrument(s) or schedule(s) of the alliance that were not read; whatever they say about improvements or training is UNMEASURED, never taken as silence: ImmatixBiotechnologies-ModernaTx Master-Collaboration-and-License 2023-09-07 (3); LieberInstitute-BullFrogAi Data-Use-and-Technology-Partnership 2023-09-07 (1); RubriCyte-iBio Collaboration-and-License 2021-08-23 (1). Each is named in that folder's read (unread_instruments).

Review state

Review findings ledger (analyze/R3b/ledger.json), rendered: findings CLOSED 45, OPEN_DEFERRED 10; re-opened earlier closures CLOSED 19, OPEN_DEFERRED 2.

Ledger note: 2026-10-12: closures are the lead's record; no fresh independent check of the fixes has been run.

Ledger note: 2026-10-13: the fresh independent check (R3c) has now been run. It found 9 of the closures in this ledger failing; those, and its new findings, are in analyze/R3c/ledger.json.

Fresh-check ledger (analyze/R3c/ledger.json), rendered: findings MUST_FIX CLOSED_BY_LEAD 3, MUST_FIX CLOSED_BY_MARK 1, NOTE CLOSED_BY_LEAD 2, NOTE CLOSED_BY_MARK 3, NOTE OPEN 26, SHOULD_FIX CLOSED_BY_LEAD 3, SHOULD_FIX CLOSED_BY_MARK 6, SHOULD_FIX CLOSED_BY_REVIEW 2, SHOULD_FIX OPEN 10; R3b closures it failed OPEN 9; article scope checks it failed CLOSED_BY_MARK 3.

Ledger note: 2026-10-13: closures are the lead's record (the same session that applied Mark's R3c rulings); they have not been re-checked by a fresh reviewer.

Ledger note: 2026-10-13 (Article 22 session): Mark's rulings R3c-3..R3c-9 close 7 findings as CLOSED_BY_MARK; the trace fixes for R3c-DT-02, R3c-DT-04 and R3c-ART-01 are applied but stay OPEN until a fresh reviewer re-checks them (R3c-10).

Article 22 session re-check ledger (analyze/R3d/ledger.json), rendered: findings NOTE OPEN 26, SHOULD_FIX CLOSED_BY_MARK 5, SHOULD_FIX OPEN 13.

Ledger note: 2026-10-17: R3d run by four fresh reviewers (brief 6b1dddbb). Mark decided five Article 22 findings (A22-02, -03, -05 reworded; A22-01, -04 kept); the reworded sentences have not been re-checked by a fresh reviewer. All other findings stay OPEN; none moves an Article 22 number.